Drugs / GEN1029
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03576131 | Apr 2018 → Oct 2021 | colorectal cancer, gastric cancer, malignant pancreatic neoplasm, non-small cell lung carcinoma +3 | Genmab | Terminated | No outcome recorded Stop: Business |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GEN1029 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03576131 ↗ |
| Route | Intravenous | “GEN1029 will be administered intravenously.” NCT03576131 ↗ |